Clinical Trials
Abivax gets approval to conduct Covid-19 trial in France
Biotechnology company Abivax has secured approval from France’s National Agency for the Safety of Medicines (ANSM) and French Ethics Committee (CPP) to conduct a Phase IIb/III clinical trial of ABX464 in Covid-19 patients.
The miR-AGE trial will assess the drug...
Clinical Trials
Vibalogics announces collaboration to provide additional clinical trial material for covid-19 vaccine candidate
Vibalogics, a global contract development and manufacturing organization (CDMO) that specializes in the production of virotherapy products, announced that it will manufacture additional clinical trial material for the lead COVID-19 vaccine candidate currently in development by the Janssen Pharmaceutical...
Clinical Trials
Greenphire Enhances Its Participant Payment and Reimbursement Solution to Further Support Remote Clinical Trials
As the COVID-19 pandemic continues to limit movement all over the world, clinical trials have had to adapt by leveraging methodologies typically associated with hybrid or remote clinical trial designs. The alternative would be to suspend the trial and...
Clinical Trials
Humanigen Initiates Phase III Lenzilumab Study in COVID-19
Humanigen, Inc., has dosed the first COVID-19 patient in its Phase III study for lenzilumab, its Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody. Catalent provides clinical supply support to Humanigen and its partners from its Philadelphia facility.
“We...
Clinical Trials
Bioclinica Launches COVID-19 Clinical Endpoint Adjudication Solution
Bioclinica has introduced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica's new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team,...
Clinical Trials
Catalent Partners with Humanigen to Support FDA-Approved Phase 3 Lenzilumab Study for COVID-19
Catalent, a global leader in clinical supply services, welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating...
Clinical Trials
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company has initiated Phase 3 clinical trials in India on Antiviral tablet Favipiravir, for which it received approval from India’s drug regulator DCGI in late April. Glenmark is the first company in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















